A Single- and Multiple-Ascending Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of LY3127760 in Healthy Subjects

Trial Profile

A Single- and Multiple-Ascending Dose, Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of LY3127760 in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Jun 2014

At a glance

  • Drugs LY 3127760 (Primary) ; Celecoxib
  • Indications Unspecified
  • Focus Adverse reactions
  • Sponsors Eli Lilly
  • Most Recent Events

    • 30 Apr 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 05 Feb 2014 Planned End Date changed from 1 Jun 2014 to 1 Apr 2014 according to ClinicalTrials.gov record.
    • 19 Nov 2013 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top